Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Intravenous recombinant tissue-type plasminogen-activator in patients with unstable angina-pectoris - results of a placebo-controlled, randomized trial

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Williams, D. O.
  • Topol, Eric
  • Califf, R. M.
  • Roberts, R.
  • Mancini, G. B. J.
  • Joelson, J. M.
  • Ellis, S. G.
  • Kleiman, N. S.

publication date

  • August 1990

journal

  • Circulation  Journal

abstract

  • Because thrombus formation may contribute to coronary obstruction in patients with unstable angina pectoris, we performed a pilot investigation to determine whether thrombolytic therapy can relieve coronary narrowing in this acute ischemic syndrome. Sixty-seven patients with rest angina and angiographic evidence of coronary stenosis were randomly assigned to receive either low-dose intravenous recombinant tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour), high-dose intravenous rt-PA (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours), or intravenous placebo followed by repeat coronary angiography at 24-48 hours to assess change in the severity of coronary narrowing. Each patient also received oral aspirin and intravenous heparin. Mean values of coronary stenosis severity (percent of diameter reduction) declined to a similar extent in each group: placebo, 75 +/- 14% to 72 +/- 14% (p = 0.07); low-dose rt-PA, 75 +/- 16% to 71 +/- 18% (p = 0.03), and high-dose rt-PA, 82 +/- 11% to 77 +/- 17% (p = 0.18), with only the low-dose rt-PA group achieving statistical significance. Resolution of intracoronary filling defects, increase in antegrade flow grade, or both also occurred equally among the three groups. There was considerable variation in individual patient response. Between 29% and 50% of patients within each group demonstrated a decrease in stenosis severity, whereas 50% to 57% noted either improvement in antegrade flow or resolution of intracoronary thrombus. There was no difference in incidence of major bleeding events among the three groups.(ABSTRACT TRUNCATED AT 250 WORDS)

subject areas

  • Aged
  • Angina Pectoris
  • Angina, Unstable
  • Angiography
  • Aspirin
  • Cardiac Catheterization
  • Coronary Angiography
  • Drug Combinations
  • Hemorrhage
  • Heparin
  • Humans
  • Injections, Intravenous
  • Patient Compliance
  • Placebos
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Tissue Plasminogen Activator
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0009-7322

PubMed ID

  • 2115407
scroll to property group menus

Additional Document Info

start page

  • 376

end page

  • 383

volume

  • 82

issue

  • 2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support